Related Experiment Video

Updated: Jul 30, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.2K

PARP inhibitors in metastatic prostate cancer

Amy K Taylor1, David Kosoff1,2, Hamid Emamekhoo1,2

  • 1Department of Medicine, University of Wisconsin, Madison, WI, United States.

Frontiers in Oncology
|May 11, 2023
PubMed

Insights

Poly-ADP ribose polymerase inhibitors (PARPi) offer a new treatment for prostate cancer by targeting synthetic lethality in homologous recombination repair deficient cells. Research aims to identify predictive biomarkers for PARPi therapy and explore combination strategies to overcome resistance.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Poly-ADP ribose polymerase inhibitors (PARPi) represent an emerging therapeutic strategy for prostate cancer.
  • PARPi function by inducing synthetic lethality in cancer cells with homologous recombination repair (HRR) deficiencies.

Purpose of the Study:

  • To review the current landscape of PARPi in prostate cancer treatment.
  • To discuss the mechanism of action, predictive biomarkers, and future directions for PARPi therapy.

Main Methods:

  • Literature review of clinical trials and research studies on PARPi in prostate cancer.
  • Analysis of the role of HRR pathway alterations in predicting PARPi response.
  • Exploration of resistance mechanisms and combination therapy strategies.

Main Results:

  • PARPi have demonstrated objective tumor responses and improved survival in metastatic castrate-resistant prostate cancer (mCRPC) with HRR alterations.
  • Olaparib and rucaparib are FDA-approved PARPi for mCRPC.
  • Identifying specific HRR alterations is crucial for optimizing PARPi utilization.

Conclusions:

  • PARPi are effective in select mCRPC patients with HRR deficiencies.
  • Further research is needed to refine patient selection and overcome treatment resistance.
  • Combination therapies hold promise for enhancing and prolonging treatment efficacy.
Keywords:
BRCADNA damage repair genesPARP inhibitorhomologous recombination repairprostate cancer

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.9K
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
228
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K